Form 4: Arteris VP Sells Shares Under 10b5-1 Plan

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold a total of 2,702 shares of common stock in early September 2025 under a pre-arranged 10b5-1 trading plan.

Summary

• Paul L. Alpern, VP and General Counsel of Arteris, Inc. (AIP), reported the sale of common stock.
• On September 8, 2025, 424 shares were sold at a price of $8.98 per share.
• On September 9, 2025, an additional 2,278 shares were sold at a weighted average price of $8.689 per share, with prices ranging from $8.51 to $8.82.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Alpern on June 5, 2025.
• Following these sales, Mr. Alpern beneficially owns 73,587 shares of Arteris, Inc. common stock.

Sentiment

Score: 5

Explanation: While an insider sale can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about it being a reaction to new, undisclosed negative information. It's a routine personal financial management event.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, undisclosed negative information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the insider's direct equity stake in the company.
• The sale occurred at prices below $9.00 per share, specifically $8.98 and a weighted average of $8.689.

Future Outlook

This filing is a routine disclosure of an insider stock transaction and does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitors. Insider sales under 10b5-1 plans are common across industries as executives manage personal finances and diversify portfolios.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a slight negative signal, though the 10b5-1 plan context reduces this impact. It indicates a reduction in direct insider ownership.

Key Dates

Recommendation

The filing reports a routine insider sale executed under a pre-established 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. This type of transaction typically does not reflect new material information about the company's performance or outlook. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Arteris Inc., AIP, Paul L. Alpern, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, corporate governance, executive compensation